MedTrace Logo

Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices

NCT01426087 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2011-09-02

No results posted yet for this study

Summary

The main complications of cirrhosis are ascites, esophageal varices and hepatic encephalopathy. About 30% to 70% patients with cirrhosis occur esophageal varices, and the most common complication is ascites. Somatostatin is used to treat esophageal for a long time, otherwise it could aslo prevent ascites. In the study, the investigators explore the effects of somatostatin on post-endoscopic portal hemodynamic in cirrhotic patients with esophageal gastric varices.

Conditions

  • Esophageal Varices Secondary to Cirrhosis of Liver

Interventions

DRUG

Somatostatin

giving stilamin 250ug/h after endoscopic therapy for 5 days

PROCEDURE

endoscopic therapy

gastroscope plus EIS/EVL/HI

Sponsors & Collaborators

  • Yunsheng Yang

    lead OTHER

Principal Investigators

  • Yun Sh Yang, Pro. · Chinese PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-10-31
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426087 on ClinicalTrials.gov